Associations of human intestinal Dorea and glucose intolerance in people with obesity / 中华内分泌代谢杂志

Objective:To evaluate the role of Dorea in glucose intolerance of people with obesity. Methods:This study recruited 113 young individuals with obesity and varying degree of glucose tolerance [body mass index(BMI)≥30 kg/m 2] and 105 controls, comparing the metabolic phenotypes and Dorea abundance. Correlation analysis and ROC analysis were performed to assess the association between Dorea and clinical parameters and its predictive role in predicting glucose intolerance. Results:(1) Metabolic parameters were higher in obesity group than the control group. There was no difference in body weight, BMI and WHR among subgroups classified by glucose tolerance in people with obesity. (2) The abundance of Dorea, Dorea formicigenerans were higher in obese individuals, however showing a downward trend in accordance with glucose intolerance. The abundance was inversely associated with OGTT-2 h plasma glucose and HbA 1C, while positively associated with HOMA-β. Logistic regression demonstrated that Dorea formicigenerans was an independent protective factor after adjusting confounders such as age and gender in the prevention of glucose intolerance. (3) ROC analysis exhibited that the AUC values of Dorea formicigenerans was 0.73 in the total population. Conclusion:Dorea and Dorea formicigenerans exert protective effect on glucose metabolism in obese subjects. The abundance of Dorea and Dorea formicigenerans can be used as predictors of glucose intolerance risk in obese subjects, which facilitate the early screening and monitoring.

Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome? / O monitoramento contínuo da glicose pode prever diabetes relacionado à fibrose cística e pior desfecho clínico?

ABSTRACT Objective: To determine whether abnormal continuous glucose monitoring (CGM) readings (hypoglycemia/hyperglycemia) can predict the onset of cystic fibrosis-related diabetes (CFRD) and/or clinical impairment (decline in BMI and/or FEV1) in pediatric patients with cystic fibrosis (CF). Methods: This was a longitudinal prospective cohort study involving CF patients without diabetes at baseline. The mean follow-up period was 3.1 years. The patients underwent 3-day CGM, performed oral glucose tolerance test (OGTT), and had FEV1 and BMI determined at baseline. OGTT, FEV1, and BMI were reassessed at the end of the follow-up period. Results: Thirty-nine CF patients (10-19 years of age) had valid CGM readings at baseline, and 34 completed the follow-up period (mean = 3.1 ± 0.5 years). None of the study variables predicted progression to CFRD or were associated with hypoglycemic events. CGM could detect glucose abnormalities not revealed by OGTT. Patients with glucose levels ≥ 140 mg/dL, as compared with those with lower levels, on CGM showed lower BMI values and z-scores at baseline-17.30 ± 3.91 kg/m2 vs. 19.42 ± 2.07 kg/m2; p = 0.043; and −1.55 ± 1.68 vs. −0.17 ± 0.88; p = 0.02, respectively-and at the end of follow-up-17.88 ± 3.63 kg/m2 vs. 19.95 ± 2.56 kg/m2; p = 0.039; and −1.65 ± 1.55 vs. −0.42 ± 1.08; p = 0.039. When comparing patients with and without CFRD, the former were found to have worse FEV1 (in % of predicted)-22.67 ± 5.03 vs. 59.58 ± 28.92; p = 0.041-and a greater decline in FEV1 (−36.00 ± 23.52 vs. −8.13 ± 17.18; p = 0.041) at the end of follow-up. Conclusions: CGM was able to identify glucose abnormalities not detected by OGTT that were related to early-stage decreases in BMI. CGM was ineffective in predicting the onset of diabetes in this CF population. Different diagnostic criteria for diabetes may be required for individuals with CF.

RESUMO Objetivo: Verificar se leituras de continuous glucose monitoring (CGM, monitoramento contínuo da glicose) anormais (hipoglicemia/hiperglicemia) podem prever o aparecimento de diabetes relacionado à fibrose cística (DRFC) e/ou comprometimento clínico (declínio do IMC e/ou do VEF1) em pacientes pediátricos com fibrose cística (FC). Métodos: Estudo de coorte longitudinal prospectivo envolvendo pacientes com FC sem diabetes no início do estudo. O tempo médio de acompanhamento foi de 3,1 anos. Os pacientes foram submetidos a CGM de três dias, teste oral de tolerância à glicose (TOTG) e medida de VEF1 e IMC no início do estudo. TOTG, VEF1 e IMC foram reavaliados ao final do acompanhamento. Resultados: Trinta e nove pacientes com FC (10-19 anos de idade) apresentaram leituras de CGM válidas no início do estudo, e 34 completaram o acompanhamento (média = 3,1 ± 0,5 anos). Nenhuma das variáveis estudadas previu evolução para DRFC ou apresentou associação com eventos hipoglicêmicos. O CGM conseguiu detectar anormalidades glicêmicas não reveladas pelo TOTG. Pacientes com níveis de glicose ≥ 140 mg/dL no CGM, comparados àqueles com níveis menores, apresentaram valores de IMC e escores z de IMC menores no início do estudo - 17,30 ± 3,91 kg/m2 vs. 19,42 ± 2,07 kg/m2; p = 0,043; e −1,55 ± 1,68 vs. −0,17 ± 0,88; p = 0,02, respectivamente - e no final do acompanhamento - 17,88 ± 3,63 kg/m2 vs. 19,95 ± 2,56 kg/m2; p = 0,039; e −1,65 ± 1,55 vs. −0,42 ± 1,08; p = 0,039. Na comparação dos pacientes com e sem DRFC, os primeiros apresentaram pior VEF1 (em % do previsto) - 22,67 ± 5,03 vs. 59,58 ± 28,92; p = 0,041 - e maior declínio do VEF1 (−36,00 ± 23,52 vs. −8,13 ± 17,18; p = 0,041) no final do acompanhamento. Conclusões: O CGM foi capaz de identificar anormalidades glicêmicas não detectadas pelo TOTG que se relacionaram com reduções precoces do IMC. O CGM foi ineficaz na previsão do aparecimento de diabetes nesta população com FC. Diferentes critérios diagnósticos para diabetes podem ser necessários para indivíduos com FC.

Prevalence of Glucose Intolerance in Early Postpartum and Its Associated Factors Among Women With History of Gestational Diabetes Mellitus

@#Introduction: Gestational diabetes mellitus (GDM) is a known risk of developing type 2 diabetes mellitus in the future. The prevalence of glucose intolerance in the early postpartum period among women with GDM ranges between 13.5% to 50%, depending on the population. This study aims to estimate the prevalence of glucose intolerance 6 to 12 weeks postpartum and its associated factors among women with GDM in Putrajaya, a federal government administrative centre of Malaysia. Methods: All women with history of GDM who had oral glucose tolerance test (OGTT) done 6 to 12 weeks postpartum at Putrajaya clinic from June 2013 to December 2016 were included. Sociodemographic data, details of GDM diagnosis and management, and postpartum OGTT results were collected. Results: There were 443 women with a mean age of 31.7 years. Postpartum OGTT showed 58 (13.2%) had prediabetes and 10 (2.1%) had diabetes. The independent risk factors associated with early postpartum glucose intolerance were 2-hour plasma glucose of diagnostic OGTT, gestational age of GDM diagnosis and HbA1c level in pregnancy. Conclusion: A diagnosis of postpartum glucose intolerance can occur early in women with history of GDM. Factors such as 2-hour plasma glucose of diagnostic OGTT, gestational age of GDM diagnosis and HbA1c level increase the risk of postpartum glucose intolerance.

Metabolic compromise in women with PCOS: earlier than expected

SUMMARY Polycystic ovary syndrome (PCOS) is an endocrinopathy with unknown pathophysiology among women of reproductive age. Several studies have been conducted to determine the prevalence of metabolic syndrome (MetS) among PCOS patients. Recent studies have reported varied prevalence of metabolic syndrome (MetS) in women with PCOS. The aim of this study is to determine if women with PCOS are at a higher risk of MetS or some degree of metabolic compromise. METHODS: This is an observational study. A total of 96 women diagnosed with PCOS (according to the Rotterdam consensus criteria) were included. Variables of diagnostic criteria for MetS according to the ATP III were analyzed at the first consultation. Data analysis was performed using Epi Info™ 7.2.2.16. RESULTS: We assessed the prevalence of obesity, blood pressure, glucose intolerance, and dyslipidemia in 96 women with PCOS and an average age of 28 (17-39) years. Forty percent of the women had BMI <25 kg/m2; 85.4% had blood pressure <130/85 mm Hg; 22.9% had HDL cholesterol >50 mg/dl, 57.3% had triglycerides <150 mg/dl, 63.5% had fasting glucose <100 mg/dl. According to the ATP III criteria for MetS, 8.33% met none of the criteria, 19.79% met one criterion, 15.63% two criteria, 41.67% 3 criteria, 13.54% 4 criteria, and 1.04% met the 5 criteria. CONCLUSION: Considering the high prevalence of MetS or altered metabolic components in PCOS patients at the moment of the diagnosis, its regular screening is necessary to reduce the mortality and morbidity rates in these women.

RESUMO A síndrome dos ovários policísticos (SOP) é uma endocrinopatia com fisiopatologia desconhecida em mulheres em idade reprodutiva. Vários estudos foram realizados para determinar a prevalência da síndrome metabólica (SM) em pacientes com SOP. Estudos recentes relataram prevalência variada de síndrome metabólica (SM) em mulheres com SOP. O objetivo deste estudo é determinar se as mulheres com SOP apresentam maior risco de SM ou algum grau de comprometimento metabólico. MÉTODOS: Estudo de desenho observacional. Foram incluídas 96 mulheres diagnosticadas com SOP (de acordo com os critérios de consenso de Roterdã). Variáveis de critérios de diagnóstico para SM de acordo com o ATP III foram analisadas na primeira consulta. A análise dos dados foi realizada usando o Epi Info™ 7.2.2.16. RESULTADOS: Avaliamos prevalência de obesidade, pressão arterial, intolerância à glicose e dislipidemia em 96 mulheres com SOP, com idade de 28 (17-39) anos. Quarenta por cento das mulheres tinham IMC <25 kg/m2; 85,4% tinham pressão arterial <130/85 mm Hg; 22,9% tinham colesterol HDL >50 mg/dl, 57,3% tinham triglicerídeos <150 mg/dl, 63,5% tinham glicemia de jejum <100 mg/dl. Segundo os critérios do ATP III para SM, 8,33% não possuíam critérios, 19,79% possuíam um critério, 15,63% possuíam dois critérios, 41,67% possuíam três critérios, 13,54% possuíam quatro critérios, 1,05% possuía os cinco critérios. CONCLUSÃO: Considerando a alta prevalência de SM ou algum componente metabólico alterado em pacientes com SOP no momento do diagnóstico, sua triagem regular é necessária para reduzir as taxas de mortalidade e morbidade nessas mulheres.

La amarga realidad de los edulcorantes no nutritivos: desde una perspectiva global al contexto chileno / The bitter reality of non-nutritive sweeteners: a global perspective applied to the Chilean context

Actualmente los edulcorantes no nutritivos (ENN) son ampliamente usados para endulzar los alimentos en reemplazo de los azúcares simples, con la ventaja de no aportar energía. A pesar de que en general no presentan efectos tóxicos, los estudios epidemiológicos no han podido evidenciar que su uso contribuya a mejorar la pérdida de peso, sino por el contrario, han revelado que los ENN pueden inducir alteraciones metabólicas como intolerancia a la glucosa. Estudios in vivo e in vitro han mostrado que muchos ENN activan a receptores del sabor dulce no sólo en los botones gustativos, sino que también en los receptores presentes en tejidos como el adiposo y pancreático, interfiriendo con su función normal. Además, el consumo ENN se ha asociado a alteraciones de la composición de la microbiota intestinal que conducen a una respuesta inflamatoria de bajo grado. La nueva evidencia disponible sobre los ENN hace necesario evaluar el uso cada vez más intenso de los ENN en Chile. Debido a que el gusto exacerbado por el sabor dulce que cultivamos desde la infancia es un potente catalizador del uso de ENN, proponemos que una oportuna educación del sentido del gusto puede contribuir a mejorar las elecciones alimentarias.

Currently, non-nutritive sweeteners (NNS) are widely used to sweeten foods instead of simple sugars, as they possess the advantage of not contributing to energy intake. Although they do not present toxic effects in general, epidemiological studies have not been able to show benefits when they are used in weight loss programs. However, they could induce metabolic alterations such as glucose intolerance. In vivo and in vitro studies have shown that many NNSs activate sweet taste receptors not only in the taste buds, but also in receptors present in adipose and pancreatic tissues, interfering with their normal function. In addition, NNS consumption has been associated with an alteration in the composition of the gut microbiota that leads to a low-grade inflammatory response. Due to the wide use of NNS in Chile, it is necessary to evaluate the potential health effects of using NNS in the Chilean population. We propose that a timely education of the sense of taste can contribute to moderating the preference for higher levels of sweet taste that humans develop in childhood, which could help to improve food choices.

Vitamin D Deficiency at Mid-Pregnancy Is Associated with a Higher Risk of Postpartum Glucose Intolerance in Women with Gestational Diabetes Mellitus

BACKGROUND: To evaluate the association between serum 25-hydroxyvitamin D (25(OH)D) at mid-pregnancy and postpartum glucose intolerance in women with gestational diabetes mellitus (GDM).METHODS: We enrolled 348 pregnant women diagnosed with GDM from August 2012 to October 2016. We measured serum 25(OH)D levels at mid-pregnancy and carried out a 75-g oral glucose tolerance test at 6 to 12 weeks after delivery. Vitamin D deficiency was defined as serum 25(OH)D <20 ng/mL.RESULTS: The prevalence of vitamin D deficiency was 76.7% (n=267). Women with vitamin D deficiency had a higher prevalence of postpartum glucose intolerance than did those without vitamin D deficiency (48.7% vs. 32.1%, P=0.011). Serum 25(OH)D level was negatively correlated with hemoglobin A1c at antepartum and postpartum period (antepartum: r=−0.186, P=0.001; postpartum: r=−0.129, P=0.047). Homeostasis model assessment of β-cell function was positively correlated with serum 25(OH)D level only postpartum (r=0.138, P=0.035). The risk of postpartum glucose intolerance was 2.00 times (95% confidence interval, 1.13 to 3.55) higher in women with vitamin D deficiency than in those without vitamin D deficiency (P=0.018).CONCLUSION: In women with GDM, vitamin D deficiency at mid-pregnancy is associated with an elevated risk of postpartum glucose intolerance.

Tpeak-Tend, Tpeak-Tend dispersion and Tpeak-Tend/QT in children and its relationship with clinical variables

Abstract Aim: To characterize the Tpeak-Tend, the Tpeak-Tend dispersion and Tpeak-Tend/QT in children and its relationship with clinical variables. Methods: Cross-sectional study in 126 children between 9 and 12 years of the Camilo Cienfuegos School in Santa Clara, Cuba. Clinical and anthropometric variables were obtained to determine their relationship with electrocardiographic parameters: Tpeak-Tend V5, Tpeak-Tend dispersion and Tpeak-Tend/QT ratio V5. In addition, laboratory tests were conducted. Results: Age and systolic blood pressure are associated with an increased probability of having values of Tpeak-Tend/QT V5 ≥75 percentile for both sexes (OR: 1.72, CI 95%: 1.02-2.91; p= 0.043), (OR: 1.08, CI 95%: 1.01-1.16; p= 0.017) respectively. The body mass index and systolic blood pressure are linearly and significantly correlated with the Tpeak-Tend/QT V5 (r= 0.224; p= 0.012) and (r= 0.220; p= 0.014) respectively. Conclusions: The age of the patients and the systolic blood pressure figures are factors that increase the probability of having values of the Tpeak-Tend/QT V5 ≥75 percentile. There was a significant linear correlation between the Tpeak-Tend/QT V5 with the body mass index and the systolic blood pressure.

Resumen Objetivo: Caracterizar el Tpico-Tfinal, la dispersión del Tpico-Tfinal y el Tpico-Tfinal/QT en niños y su relación con variables clínicas. Métodos: Estudio transversal en 126 niños entre 9 y 12 años de la escuela Camilo Cienfuegos en Santa Clara, Cuba. Se obtuvieron variables clínicas y antropométricas para determinar su relación con los parámetros electrocardiográficos: el Tpico-Tfinal V5, la dispersión del Tpico-Tfinal y el Tpico-Tfinal/QT V5. Además, se realizaron pruebas de laboratorio. Resultados: La edad y la presión arterial sistólica se asocian con una mayor probabilidad de tener valores del Tpico-Tfinal/QT V5 ≥75 percentil para ambos sexos (OR: 1.72, IC 95%: 1.02-2.91; p= 0.043), (OR: 1.08, IC 95%: 1.01-1.16; p= 0.017) respectivamente. El índice de masa corporal y la presión arterial sistólica están correlacionados de manera lineal y significativa con el Tpico-Tfinal/QT V5 (r= 0.224; p= 0.012) y (r= 0.220; p= 0.014) respectivamente. Conclusiones: La edad de los pacientes y las cifras de presión arterial sistólica son factores que aumentan la probabilidad de tener valores del percentil Tpico-Tfinal/QT V5 ≥75. Existe correlación lineal significativa entre el Tpico-Tfinal/QT V5 con el índice de masa corporal y la presión arterial sistólica.

Fetomaternal outcome in patients with diabetes mellitus in pregnancy

Background: Diabetes mellitus (DM) is defined as increased blood glucose level due to defect in insulin secretion, insulin action or both. Undiagnosed or inadequately treated diabetes mellitus during pregnancy can lead to significant maternal and fetal complications. The study was conducted to review feto-maternal outcome in pregnancy with diabetes and to plan management of pregnancy with diabetes and to study the modalities for treatment of DM in pregnancy.Methods: A prospective case study was conducted from July 2015 to December 2018 at a tertiary care center. Study group used single step 75gm oral glucose tolerance test (OGTT) test recommended by WHO for GDM diagnosis.Results: GDM (85%) was more common than overt diabetes (15%) and in younger age group (53.75%) and Multiparous patients (18.2%). Most of patients required insulin (81.2%) for treatment of DM during pregnancy along with medical nutrition therapy and exercise. Most common association in this patient was hypertension (41%). Rate of caesarean section (60%) was more common. Average birth weight was of >3.5 kg, intrauterine death (4.2%), preterm delivery (14.2%) and admission to NICU were also common.Conclusions: There was significant fetomaternal morbidity in patients with diabetes mellitus. Early diagnosis and treatment reduces the fetomaternal outcome.

Efectos de la terapia periodontal con antibióticos tópicos en el control glicémico de pacientes diabéticos: revisión sistemática / Effects of periodontal therapy with topical antibiotics in the glycemic control of diabe tic patients: systematic review

Background: Periodontal disease is considered as a diabetes complication and has been suggested that periodontal treatment plus antibiotics should reduce glycated hemoglobin A, by reducing local production of pro inflammatory substances. Objective: To evaluate diabetic patients with periodontal disease under periodontal treatment plus topical antibiotics and reduction of HbA1c, compared to diabetic patients under periodontal treatment without antibiotics. Materials and Methods: Using PUBMED, SCOPUS, WEB OF SCIENCE, EMBASE and Google Scholar data bases, were screened documents from 2008 to 2018. The documents included were the clinical studies, which included non-surgical periodontal treatment plus topical antibiotics, whose outcomes included the HbA1c report. Two independent researchers evaluate title; abstract and bias risk with Downs Black scale and Cochrane tool. Documents with a score higher than 15 on average by the two evaluators were included. Results: Five articles, which find inclusion criteria, were identified. Two documents failed to demonstrate statistically significant effect when compared to non-surgical periodontal therapy alone. Conclusion: In general a modest reduction of HbA1c was identified when using antibiotic therapy.

Antecedentes: La enfermedad periodontal es considerada una complicación del paciente diabético y se ha sugerido que su tratamiento con o sin antibióticos podría aportar a la reducción de la hemoglobina glucosilada, al reducir la producción local de sustancias pro-inflamatorias. Objetivo: Evaluar pacientes diabéticos con enfermedad periodontal que recibieron terapia periodontal no quirúrgica (TPNQ) más antibióticos tópicos y la reducción de la hemoglobina glucosilada, comparados con pacientes que recibieron TPNQ sin antibióticos tópicos. Materiales y métodos: Se utilizaron bases de datos MEDLINE vía PubMed, WEB OF SCIENCE, SCOPUS, EMBASE y Google Scholar utilizando vocabulario controlado y limitando la búsqueda a los años 2008-2018. Los documentos incluidos fueron los estudios clínicos, que incluían tratamiento periodontal no quirúrgico mas antibióticos tópicos, cuyos desenlaces incluyeran el reporte de HbA1c. Estos fueron analizados por dos evaluadores independientes, para identificación de riesgo de sesgo con la escala Downs Black y herramienta Cochrane. Se incluyeron los documentos con puntuación mayor a 15 en promedio de los dos evaluadores. Resultados: Se identificaron 5 documentos que cumplen con los criterios de inclusión. Dos documentos no mostraron diferencias estadísticamente significativas para el cambio de la HbA1c, en comparación con la terapia periodontal sola. Conclusión: En general se evidencia una discreta reducción de HbA1c con la terapia periodontal usando antibióticos tópicos.

Glucemia en ayunas alterada versus prueba de tolerancia a la glucosa alterada. Resultados perinatales. Cienfuegos, 2016 / Impaired fasting glycemia versus impaired glucose tolerance test. Perinatal results. Cienfuegos, 2016

RESUMEN Fundamento: Las cifras de glucemia materna alteradas pueden causar morbimortalidad perinatal. El estudio de la glucemia en ayunas alterada en gestantes es un tópico que reviste gran importancia, dada su repercusión en los resultados perinatales; y requiere de nuevos análisis, en correspondencia con los criterios actuales. Objetivo: comparar los resultados perinatales de gestantes con glucemia en ayunas alterada, con los de aquellas que presentaron una prueba de tolerancia a la glucosa alterada. Métodos: se realizó un estudio descriptivo, en el servicio de Obstetricia del Hospital Dr. Gustavo Aldereguía Lima, de Cienfuegos, de enero a diciembre de 2016. Se trabajó con 144 gestantes con diagnóstico de diabetes mellitus gestacional, según criterios de la Organización Mundial de la Salud, y se dividieron según los criterios diagnósticos en: pacientes con glucemia en ayunas alterada y pacientes con prueba de tolerancia a la glucosa alterada. Se compararon ambos grupos en cuanto a variables clínicas y resultados perinatales. Se utilizó el Chi cuadrado (p<0,05) y se calculó la razón de riesgo (IC 95 %). Resultados: los grupos comparados exhibieron resultados similares en cuanto a edad, índice de masa corporal, tiempo de embarazo al diagnóstico, paridad, tratamiento, edad gestacional al parto; así como en los resultados perinatales: tasa de inducción del parto y cesárea, malformaciones congénitas, macrofeto y bajo peso, asfixia neonatal, ventilación neonatal e ingreso en cuidados intensivos neonatales. Conclusión: las gestantes con glucemia en ayunas alterada mostraron características clínicas y resultados perinatales similares a las gestantes con prueba de tolerancia a la glucosa alterada.

ABSTRACT Foundation: Impaired maternal glycemia figures can cause perinatal morbidity and mortality. The study of impaired fasting blood glucose in pregnant women is of relevant importance, due to its impact on perinatal outcomes; and it requires new analyzes, in correspondence with the current criteria. Objective: to compare perinatal results of pregnant women with impaired fasting glycaemia, with those of those who presented an impaired glucose tolerance test. Methods: a descriptive study was carried out in the obstetrics department of the Dr. Gustavo Aldereguía Lima Hospital, in Cienfuegos, from January to December 2016. A number of 144 pregnant women diagnosed with gestational diabetes mellitus, according to criteria of the World Health Organization were studied and were divided according to the diagnostic criteria in: patients with impaired fasting blood glucose and patients with impaired glucose tolerance test. Both groups were compared in terms of clinical variables and perinatal results. Square Chi was used (p <0.05) and the risk ratio was calculated (95 % CI). Results: the groups compared showed similar results in terms of age, body mass index, time of pregnancy at diagnosis, parity, treatment, gestational age at birth; as well as in the perinatal results: rate of labor induction and cesarean section, congenital malformations, fetal microsomia and low weight, neonatal asphyxia, neonatal ventilation and admission to neonatal intensive care. Conclusion: pregnant women with impaired fasting blood glucose showed clinical characteristics and perinatal results similar to pregnant women with impaired glucose tolerance test.

Effect of Linagliptin versus Metformin on Insulin Secretion, Insulin Sensitivity and Glucose Control in Subjects with Impaired Glucose Tolerance / Efecto de la Linagliptina Frente a la Metformina en la Secreción de Insulina, Sensibilidad a la Insulina y Control de la Glucosa en Sujetos con Intolerancia a la Glucosa

ABSTRACT Aim: The aim of the study is to evaluate the effect of linagliptin versus metformin on insulin secretion, insulin sensitivity and glucose control in patients with impaired glucose tolerance (IGT). Patients and methods: A randomized, double-blind, clinical trial with parallel groups was per-formed on 16 adults with IGT. Lipid profile and haemoglobin (HbA1c) were evaluated prior to and after the intervention. Glucose and insulin were measured at 0, 30, 60, 90 and 120 minutes after a 75-g oral dextrose load. Eight patients received metformin (500 mg) twice a day before meals for three months. The remaining eight patients received placebo (500 mg) in the morning and linagliptin (5 mg) in the evening before meals. The area under the curve (AUC) of glucose and insulin, total insulin secretion, first-phase of insulin secretion, and insulin sensitivity were assessed. Results: After linagliptin administration, a significant decrease in glucose at 90 minutes (10.8 ± 2.6 vs 7.9 ± 2.2 mmol/L, p < 0.05), 120 minutes (8.8 ± 0.9 vs 6.5 ± 2.1 mmol/L, p < 0.05) and AUC of glucose (1168 ± 210 vs 953 ± 207 mmol/L, p < 0.05) were observed. Metformin administration decreased insulin significantly at 0 minutes (94.8 ± 25.8 vs 73.8 ± 24.6 pmol/L, p < 0.05). Conclusion: Three-month administration of linagliptin in patients with IGT decreased glucose at 90 and 120 minutes after a 75-g oral dextrose load and AUC of glucose. Metformin decreased insulin at 0 minutes.

RESUMEN Objetivo: El objetivo del estudio es evaluar el efecto de la linagliptina frente a la metformina en la secreción de insulina, la sensibilidad a la insulina, y el control de la glucosa en pacientes con intolerancia a la glucosa (IG). Pacientes y métodos: Se realizó un ensayo clínico aleatorio de doble ciego con grupos paralelos a 16 adultos con IG. El perfil lipídico y la hemoglobina (Hba1C) se evaluaron antes y después de la intervención. La glucosa y la insulina se midieron a los 0, 30, 60, 90 y 120 minutos después de un carga oral de 75-g dextrosa. Ocho pacientes recibieron metformina (500 mg) dos veces al día antes de las comidas por tres meses. Los ocho pacientes restantes recibieron placebo (500 mg) por la mañana y linagliptina (5 mg) por la noche antes de las comidas. El área bajo la curva (ABC) de la glucosa y la insulina, la secreción total de insulina, la primera fase de la secreción de insulina, y la sensibilidad a la insulina, fueron evaluadas. Resultados: Luego de la administración de la linagliptina, se observó una disminución significativa de la glucosa a los 90 minutos (10.8 ± 2.6 vs 7.9 ± 2.2 mmol/L, p < 0.05), 120 minutos (8.8 ± 0.9 mmol/L p < 0.05) y el ABC de la glucosa (1168 ± 210 vs 953 ± 207 mmol/L, p < 0.05). La administración de metformina redujo significativamente la insulina a los 0 minutos (94.8 ± 25.8 vs 73.8 ± 24.6 pmol/L, p < 0.05). Conclusión: Tres meses de administración de linagliptina en pacientes con IG disminuyó la glucosa a los 90 y 120 minutos después de una carga oral de dextrosa de 75-g y el ABC de la glucosa. La metformina disminuyó la insulina en 0 minutos.

Proportion of women with history of gestational diabetes mellitus who performed an oral glucose test at six weeks postpartum in Johor Bahru with abnormal glucose tolerance

@#Introduction: Glucose testing at six weeks postpartum has been recommended by the World Health Organization as the earliest period in which to detect abnormal glucose tolerance among women with a history of gestational diabetes mellitus (GDM). This study aimed to determine the outcomes of six weeks postpartum glucose testing and its associated factors among women with a history GDM who attended government primary health clinics in Johor Bahru. Methods: The study was a cross sectional study which was conducted among women with a history of GDM who registered from January to June 2016 at primary health clinics in Johor Bahru and underwent an oral glucose tolerance test at six weeks postpartum. Secondary data were obtained from Maternal Health Records (clinic copy). Data were analyzed using SPSS Version 23.0. Descriptive statistics and simple logistic regression analysis were used. Results: One hundred and twenty-two women with a history of GDM completed the postpartum glucose testing. Approximately 12% of these women were reported to have abnormal glucose tolerance. Insulin usage (OR:5.44; 95% CI:1.53, 19.43; p=0.009), abnormal glycated hemoglobin (OR:8.70; 95% CI:2.68,26.27; p<0.01), hospital follow-up (OR:3.38; 95% CI: 1.11, 10.34; p=0.033) and neonatal intensive care unit admission (OR:3.96; 95% CI: 1.16, 13.54; p=0.028) were found to have significant associations with abnormal glucose tolerance at six weeks postpartum. Conclusion: The proportion of women with a history of GDM and abnormal glucose tolerance at six weeks postpartum in Johor Bahru was 12% and was associated with insulin usage, abnormal glycated hemoglobin, hospital follow-up and neonatal intensive care unit admission. Screening during the postpartum period offers a window of opportunity for early identification of diabetes and prediabetes, as women with history of GDM are at increased risk of future glucose intolerance.

Metabolic Syndrome and Male Fertility

Metabolic syndrome (MetS) represents a cluster of conditions that have a negative impact on human health overall. Its prevalence has been rapidly increasing worldwide and has coincided with a global decrease in birth rates and fertility potential. This review aims to address this observation through studying the relationship between MetS and male reproductive health. The effects of obesity, dyslipidemia, hypertension, and insulin resistance on male fertility were examined and supporting evidence explaining the pathophysiology of sperm dysfunction with each MetS component were described. Adopting a healthy lifestyle appears to be the single most important intervention to prevent the unwanted effects of MetS on men's health and fertility. Further studies addressing the components of MetS and their impact on male reproduction are required to enhance our understanding of the underlying pathophysiology and to propose new methods for therapeutic intervention.

A study of post-partum persistence of glucose intolerance and its association with metabolic risk factors in gestational diabetes mellitus patients in urban South-Indian population

Background: Gestational diabetes mellitus, as a metabolic disorder affects 1%-28% of pregnancies. History of gestational diabetes is an important predictor of various metabolic disturbances later in life. This study was intended to observe the impact of the various predictors over persistence of abnormal glucose tolerance at post-partum and its association with metabolic risk factors. Materials and methods: This was a prospective study of 216 GDM women diagnosed by 75 g oral glucose tolerance test (OGTT) during index pregnancy attending diabetology OPD in Institute of social obstetrics and Kasturba Gandhi general hospital between January 2016 to March 2018. At 6-12 weeks post-partum, 75 g - 2 hr-OGTT was done to assess their glycemic status. Data for predictors and metabolic risk factors were obtained from history, clinical examination and personal records. Plasma glucose was measured by glucose-oxidase method. The results were calculated using SPSS software and expressed in percentage. Results: Of the 216 women only 173 patients came for postpartum follow up at 6- 12 weeks. Normal glucose tolerance (NGT) was seen in 58.9% and abnormal glucose tolerance (AGT) in 41.1%. The Ayyasami Revathi, Tharmaraj Ramesh Kumar. A study of post-partum persistence of glucose intolerance and its association with metabolic risk factors in gestational diabetes mellitus patients in urban South-Indian population. IAIM, 2018; 5(7): 50- 55. Page 51 frequency of abnormal glucose intolerance includes IFG: 0.9%, IGT: 24.5%, DM: 15.7%. Gestational age <20 week at detection of GDM, higher parity, insulin use during pregnancy, previous history of GDM, higher glucose levels on the diagnostic OGTT, hypertension were significantly higher in the AGT group. However positive family history of diabetes and BMI showed no statistically significant correlation. Conclusion: It is concluded that advanced age, higher parity, previous history of GDM, earlier gestational age at diagnosis of GDM and use of insulin during pregnancy are important predictors for AGT during post-partum period and hypertension as a metabolic risk factor was strongly associated with AGT. Need for early postpartum screening and implementation of various intervention program to prevent type 2 diabetes in high risk GDM women.

Prediabetes and ischemic stroke / 国际脑血管病杂志

Prediabetes is a glucose metabolism status between normal glucose metabolism and diabetes.It can not only increase the risks of occurrence and recurrence of stroke, but also affect stroke outcomes.Prediabetes causes ischemic stroke mainly through the insulin resistance and blood-brain barrier damage.Non-drug or drug intervention in patients with prediabetes can delay progression from prediabetes to diabetes and reduce the risks of occurrence and recurrence of stroke.

Adiponectin Concentration in Gestational Diabetic Women: a Case-Control Study

Gestational diabetes mellitus (GDM) is an impaired fasting glucose condition during pregnancy. Adiponectin is a polypeptide hormone that is extensively released by adipocytes which regulates energy homeostasis and carbohydrate and lipid metabolism. In addition, adiponectin has antidiabetic and anti-inflammatory properties. The aim of our research was to study about the relationship of adiponectin levels to GDM and glucose intolerance. We selected 25 GDM women and 35 healthy pregnant subjects (18–46 years) who were screened between 24 and 28 weeks of gestation based on the result of oral glucose tolerance test (OGTT). We designed a case-control study and measured the concentrations of serum adiponectin and compared the concentrations between the groups. Serum adiponectin concentration was measured using enzyme-linked immunosorbent assay (ELISA). Sociodemographic data were collected by personal interview. Serum adiponectin concentrations were significantly lower in the subjects with GDM (5.10 ± 2.15 ng/mL vs. 7.86 ± 3.52 ng/mL, p = 0.001) than in healthy pregnant subjects. The mean concentration of fasting blood glucose was considerably lower in control subjects (86.9 ± 9.0 mg/dL vs. 175.9 ± 20.1 mg/dL, p < 0.001) in comparison to GDM subjects. Our findings showed that serum concentrations of adiponectin were significantly lower in gestational diabetic women and this may help to predict the risk of GDM.

A glucose-centric perspective of hyperglycemia.

Digestion of food in the intestines converts the compacted storage carbohydrates, starch and glycogen, to glucose. After each meal, a flux of glucose (>200 g) passes through the blood pool (4-6 g) in a short period of 2 h, keeping its concentration ideally in the range of 80-120 mg/100 mL. Tissue-specific glucose transporters (GLUTs) aid in the distribution of glucose to all tissues. The balance glucose after meeting the immediate energy needs is converted into glycogen and stored in liver (up to 100 g) and skeletal muscle (up to 300 g) for later use. High blood glucose gives the signal for increased release of insulin from pancreas. Insulin binds to insulin receptor on the plasma membrane and activates its autophosphorylation. This initiates the post-insulin-receptor signal cascade that accelerates synthesis of glycogen and triglyceride. Parallel control by phos-dephos and redox regulation of proteins exists for some of these steps. A major action of insulin is to inhibit gluconeogensis in the liver decreasing glucose output into blood. Cases with failed control of blood glucose have alarmingly increased since 1960 coinciding with changed life-styles and large scale food processing. Many of these turned out to be resistant to insulin, usually accompanied by dysfunctional glycogen storage. Glucose has an extended stay in blood at 8 mM and above and then indiscriminately adds on to surface protein-amino groups. Fructose in common sugar is 10-fold more active. This random glycation process interferes with the functions of many proteins (e.g., hemoglobin, eye lens proteins) and causes progressive damage to heart, kidneys, eyes and nerves. Some compounds are known to act as insulin mimics. Vanadium-peroxide complexes act at post-receptor level but are toxic. The fungus-derived 2,5-dihydroxybenzoquinone derivative is the first one known to act on the insulin receptor. The safe herbal products in use for centuries for glucose control have multiple active principles and targets. Some are effective in slowing formation of glucose in intestines by inhibiting α–glucosidases (e.g., salacia/saptarangi). Knowledge gained from French lilac on active guanidine group helped developing Metformin (1,1-dimethylbiguanide) one of the popular drugs in use. One strategy of keeping sugar content in diets in check is to use artificial sweeteners with no calories, no glucose or fructose and no effect on blood glucose (e.g., steviol, erythrytol). However, the three commonly used non-caloric artificial sweeteners, saccharin, sucralose and aspartame later developed glucose intolerance, the very condition they are expected to evade. Ideal way of keeping blood glucose under 6 mM and HbA1c, the glycation marker of hemoglobin, under 7% in blood is to correct the defects in signals that allow glucose flow into glycogen, still a difficult task with drugs and diets.

Caracterización de los factores de riesgo de diabetes mellitus tipo 2 mediante el test de Findrisk en una población de 30 a 50 años de Medellín, Colombia / Characterization of risk factors for type 2 diabetes mellitus by Findrisk test in a population of 30 to 50 years old from Medellin, Colombia

Introducción: la diabetes mellitus es una de las enfermedades crónicas prevenibles con mayor impacto en la población mundial. Objetivo: caracterizar los factores de riesgo de diabetes mellitus tipo 2 mediante la aplicación del test de Findrisk. Materiales y métodos: se realizó un estudio piloto descriptivo que incluyó 51 personas entre 30 y 50 años, residentes en Medellín, Colombia, sin diagnóstico previo de diabetes mellitus. Se aplicó el test de Findrisk para valorar los factores de riesgo asociados a diabetes. Resultados: el 68,6% de las personas fueron mujeres. El 64,7% de la población fue menor de 45 años. El 51,0% de la población obtuvo puntaje menor que 7 (bajo), el 17,6% entre 7 y 11 (elevado levemente), el 21,6% entre 12 y 14 (moderado), el 7,8% mayor que 14 y hasta 20 (alto) y el 2,0% mayor que 20 (muy alto). El promedio del puntaje total fue 7,8. El 51,0% de la población tuvo IMC menor que 25 Kg/m2, el 66,7% no realizaba actividad física diaria, el 47,1% no consumía frutas ni verduras, el 94,1% no tenía antecedentes de niveles de glucosa altos en sangre y el 23,5% presentaba antecedentes familiares de diabetes mellitus en primer grado de consanguinidad. En el análisis de asociación la edad, el consumo de medicamentos antihipertensivos y los antecedentes familiares de diabetes mellitus tuvieron influencia significativa en el puntaje final del test. Conclusiones: el test de Findrisk es una herramienta útil para caracterizar los factores de riesgo de diabetes mellitus tipo 2. (AU)

Introduction: Diabetes mellitus is one of the preventable chronic diseases with greatest impact on global population. Objective: To characterize the risk factors for type 2 diabetes mellitus through the application of the Finnish Diabetes Risk Score. Materials and methods: A descriptive pilot study including 51 individuals between 30 and 50 years old, residing in Medellin, Colombia, without a previous diagnosis of diabetes mellitus was performed. The Finnish Diabetes Risk Score was implemented to assess the risk factors associated with diabetes. Results: 68.6% of the people were women. The 64.7% of the population were older than 45 years old. The 51.0% of the population had a score below 7 (low), 17.6% between 7 and 11 (slightly high), 21.6% between 12 and 14 (moderate), 7.8% higher than 14 and up to 20 (high), and 2.0% higher than 20 (very high). The average total score was 7.8. The 51.0% of the population got a BMI less than 25 Kg/m2, 66.7% do not performed daily physical activity, 47.1% do not eat fruit and vegetables, 94.1% do not had history of high levels of blood glucose, and 23.5% had a familiar history of diabetes mellitus with the first degree of consanguinity. In the association analysis, age, consumption of antihypertensive medicines and family history of diabetes mellitus had a considerable influence on the test final score. Conclusions: The Finnish Diabetes Risk Score is a useful tool to characterize the risk factors for type 2 diabetes mellitus. (AU)

The Effect of Glycemic Status on Kidney Stone Disease in Patients with Prediabetes

BACKGROUND: While the evidence supporting a positive association between diabetes mellitus and kidney stone disease (KSD) is solid, studies examining the association between impaired fasting glucose (IFG) and KSD show inconsistent results. Currently, there are no studies examining the relationship between impaired glucose tolerance (IGT) and KSD. The objective of this study is to investigate the effects of different glycemic statuses on KSD. The results may help to motivate patients with diabetes to conform to treatment regimens. METHODS: We conducted a cross sectional study of a population that underwent health check-ups between January 2000 and August 2009 at the Health Evaluation Center of National Cheng Kung University Hospital. A total of 14,186 subjects were enrolled. The following categories of glycemic status were used according to the criteria of the 2009 American Diabetes Association: normal glucose tolerance, isolated IGT, isolated IFG, combined IFG/IGT, and diabetes. The existence of KSD was evaluated using renal ultrasonography, and the presence of any hyperechoic structures causing acoustic shadowing was considered to be indicative of KSD. RESULTS: The prevalence of KSD was 7.4% (712/9,621), 9.3% (163/1,755), 10.8% (78/719), 12.0% (66/548), and 11.3% (174/1,543) in subjects with NGT, isolated IGT, isolated IFG, combined IFG/IGT, and diabetes, respectively. Isolated IFG, combined IFG/IGT, and diabetes were associated with KSD after adjusting for other clinical variables, but isolated IGT was not. Age (41 to 64 years vs. ≤40 years, ≥65 years vs. ≤40 years), male gender, hypertension, and hyperuricemia were also independently associated with KSD. CONCLUSION: Isolated IFG, combined IFG/IGT, and diabetes, but not isolated IGT, were associated with a higher risk of KSD.